It has significant anti-coagulation factor Xa activity, and low anti-coagulation factor IIa or antithrombin activity (30 IU/ml). It can inhibit the formation of thrombi in vivo and in vitro and arteriovenous thrombi, but does not affect platelet aggregation and the binding of fibrinogen to platelets. When it exerts its antithrombotic effect, the possibility of bleeding is small. At the recommended dose for different indications, low molecular weight heparin does not prolong bleeding time. At the preventive dose, it does not significantly change APTT.

It can convert kininogen into kinin and vasodilator, and has the effects of dilating blood vessels, inhibiting platelet aggregation, and enhancing red blood cell deformability and oxygen dissociation ability; it can increase arterial blood flow, improve cerebral microvascular damage, reduce the expansion of cerebral infarction area, improve the reduced glucose and oxygen uptake of brain tissue caused by infarction, improve glucose metabolism, and improve spontaneous cortical EEG abnormalities.

No specific pharmacological effects mentioned